Financials
- Financial year
- 2026
- Total assets
- €5.0m
- Solvency
- 51.6%
- Liquidity
- 0.00
Summary
IUVO Therapeutics is less than twelve months old; there is no public track record yet to compute a bankruptcy probability from. The 2026 annual accounts show equity of €2.6m. The company has been active since 2026 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
“L’investissement, la souscription, la prise ferme, le placement, la vente, l’achat et la négociation…” (deed in French)
From the articles, 11 activitiesNo NACE code in the KBO yet1 site
Size
€5.0mtotal assets 2026
- Equity
- €2.6m
Financial health
Too few figures to scoreToo young for a bankruptcy probability
Structure
- LUBOSCH-HAENISCH Jonathan Wolfgang BernhardDirector
- ORIANI Andrea UmbertoDirector
- SCHNARR Christopher JamesDirector
2026 accounts 186 days early
Signalsraises riskYoung companyneutralLatest accounts filed on timeShow the evidence
Checked score
No current score
Insufficient figures
A score requires measurable solvency, liquidity and profitability. Missing figures are not a judgement about the company.
Bankruptcy probability, 12 months
This company is younger than 12 months. There is no public track record yet to base a reliable estimate on, so we'd rather not show a number.
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Two signals.
raises riskneutral
raises risk · Young company
Founded in 2026, less than a year ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 04-03-2026 was due by 04-10-2026 and was filed on 01-04-2026, 186 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2026
186 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
- Capital & shares · Amendment of…Kind of shares · Capital
- Capital & shares · Amendment of…Auditor report · Capital contribution…
- Annual accounts filedfinancial year 2026 · unclassified…
Key points
By topic
Board & ownership
- Board
- 3 members
- LUBOSCH-HAENISCH Jonathan Wolfgang BernhardDirector
- ORIANI Andrea UmbertoDirector
- SCHNARR Christopher JamesDirector
Timeline
- Events
- 4
- Since
- 2026
- 06-03-2026Incorporation
Company details
- Sites
- 1
- Legal form
- Private limited company
- Founded
- 04-03-2026
- Year ends
- 04-03
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 21
- Financial year
- From 1 January to 31 December
- Annual meeting
- Last Wednesday of May at 15:00
- Purpose
- “L’investissement, la souscription, la prise ferme, le placement, la vente, l’achat et la…” (deed in French)
Key facts about IUVO Therapeutics
- What is the company number of IUVO Therapeutics?
- 1035.117.682. In Belgium the VAT number is the company number with BE in front: BE 1035.117.682.
- Where is IUVO Therapeutics based?
- The registered office is at Koloniënstraat 11, 1000 Brussel.Company details
- What is the legal form of IUVO Therapeutics?
- Private limited company (BV).
- When was IUVO Therapeutics founded?
- On 04-03-2026.
- Is IUVO Therapeutics still active?
- Yes, IUVO Therapeutics is an active enterprise in the KBO register.
- What is the turnover of IUVO Therapeutics?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
- Where can I find the annual accounts of IUVO Therapeutics?
- IUVO Therapeutics filed 1 annual account with the National Bank of Belgium, for financial year 2026.
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.